Cross-Section of Neurological Manifestations Among SARS-CoV-2 Omicron Subvariants—Single-Center Study DOI Creative Commons
Justyna Jachman-Kapułka, Aleksander Zińczuk, Krzysztof Simon

et al.

Brain Sciences, Journal Year: 2024, Volume and Issue: 14(11), P. 1161 - 1161

Published: Nov. 20, 2024

: The Omicron variant of SARS-CoV-2 is undergoing constant mutation. New strains vary in neuropathogenicity and the neurological spectrum disease. aim this study was to assess frequency clinical characteristics manifestations during dominance among hospitalized patients, including differences between three subsequent periods.

Language: Английский

Clinical profile analysis of SARS-CoV-2 community infections during periods with omicron BA.2, BA.4/5, and XBB dominance in Hong Kong: a prospective cohort study DOI
Yawei Wang, Hau Chi So, Nicole Ngai Yung Tsang

et al.

The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

Citations

3
Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season DOI Creative Commons
Aida Perramon‐Malavez, Víctor López de Rioja, Ermengol Coma

et al.

European Journal of Pediatrics, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 28, 2024

Language: Английский

Citations

1
Cross-Section of Neurological Manifestations Among SARS-CoV-2 Omicron Subvariants—Single-Center Study DOI Creative Commons
Justyna Jachman-Kapułka, Aleksander Zińczuk, Krzysztof Simon

et al.

Brain Sciences, Journal Year: 2024, Volume and Issue: 14(11), P. 1161 - 1161

Published: Nov. 20, 2024

: The Omicron variant of SARS-CoV-2 is undergoing constant mutation. New strains vary in neuropathogenicity and the neurological spectrum disease. aim this study was to assess frequency clinical characteristics manifestations during dominance among hospitalized patients, including differences between three subsequent periods.

Language: Английский

Citations

0